DeepCyte Inc. is an AI-powered biotechnology and toxicology platform headquartered in Wilmington, Delaware. Established in 2025, the company develops advanced computational tools for toxicity assessment and life sciences research.
Subscribe to see DeepCyte Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
DeepCyte Inc. is a biotechnology company headquartered in United States. Its most recent funding round raised $1.4M in January 2026. Xcout tracks 8 named people at DeepCyte Inc., including Theodore Alexandrov (CEO).
2 more named people on record for DeepCyte Inc., with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $1.4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of DeepCyte Inc.'s closest competitors — see the full list of competitors and alternatives →
Deep Cell Industries Inc. provides an AI-integrated platform called REM-I that combines label-free imaging, deep learning, and cell enrichment for single-cell morpholomic analysis. The company serves researchers and organizations in oncology, drug discovery, cell and gene therapy, and related life science fields by enabling high-resolution profiling and sorting of viable cells.
シンクサイト株式会社(ThinkCyte)は、AIと光学技術を組み合わせた高次元細胞解析技術「ゴーストサイトメトリー」を開発する日本のバイオテクノロジー企業です。製薬企業、研究機関、臨床・診断分野などに向けて、創薬研究や細胞分析のための装置・ソリューションを提供しています。
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
CytoTronics is a biotechnology research company headquartered in Boston, Massachusetts, specializing in cell-based discovery and high-density electrode array technology.
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
INDIGO Biosciences, Inc. provides life science solutions, specializing in in vitro cell-based reporter assay systems and screening services for pharmaceutical and research markets. Headquartered in State College, Pennsylvania, the company supports environmental, toxicological, and drug discovery testing.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.